IFF Health has received Non-GMO Project Verified certification for its Go-Less Men, an extract, for healthy bladder function in men. The activity of this plant-based ingredient is supported by clinical trials.
Go-Less Men is based on powerful bioactive components in pumpkin seeds (Cucurbita pepo L.), a plant used by Native Americans to facilitate the passage of urine and an integral part of European herbal medicine since 1539.
Clinical studies revealed that pumpkin seed extract can help support improved urinary flow rate and voiding time, and reduce residual urine volume in men suffering from benign prostatic hyperplasia (BPH).
Popular claim
Non-GMO is one of the fastest-growing claims in the US food industry. A key factor driving the growth of the market is the expanding demand for non-GMO products as a result of increasing consumer awareness of the sources for the products they consume.
The company was granted the new certification from the Non-GMO Project, a nonprofit organisation committed to preserving and building sources of non-GMO products, educating consumers, and providing verified non-GMO choices.
“This certification reflects IFF’s commitment to develop the highest quality ingredients with full transparency and add value to our customer’s products,” says Moran Werner Saido, Product Manager for IFF Health.
“Go-Less Men is supported by science, non-allergenic and has been shown to support the maintenance of a healthy bladder and prostate. It also is available in pharmaceutical grade.”
Go-Less Men ingredient is sourced from 100% European-grown pumpkin. It is manufactured using a proprietary decontamination procedure resulting in an oil-free pumpkin seed extract with ensured increased stability, purity and solubility. The process also eliminates susceptibility to rancidity.
Clinical support
In a recent clinical study , Go-Less Men demonstrated a capacity to lower urinary symptom frequency and severity in men with benign prostate hyperplasia (BPH).
Specifically, the results showed that 500 mg taken daily for 12 weeks provided statistically significant reductions in symptoms based on the total International Prostate Symptom Score (IPSS), and of all BPH related symptoms, with 30% of men reporting improvement of symptoms from “moderate/severe” to “mild.”